Neurotoxic Agents and Peripheral Neuropathy by Eskut, Neslihan & Koskderelioglu, Asli
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books











Neurotoxicity may develop with exposure to various substances such as  
antibiotics, chemotherapeutics, heavy metals, and solvents. Some plants and fungi 
are also known to be neurotoxic. Neurotoxicity can develop acutely within hours, or 
it can develop as a result of exposure for years. Neurotoxicity can be presented with 
central or peripheral nervous system findings such as neurobehavioral symptoms, 
extrapyramidal signs, peripheral neuropathy. Peripheral nerve fibers are affected in 
different ways by neurotoxicant injury. The pattern of injury depends on the target 
structure involved. The focus of this chapter includes signs, symptoms, pathophysi-
ology, and treatment options of neurotoxicity.
Keywords: neurodegeneration, neuropathy, neurotoxic, mechanisms of 
neurotoxicity, chemicals
1. Introduction
The direct or indirect effects of chemical or physical agents that disrupt the 
function or structure of the nervous system of humans or animals are called  
neurotoxicants [1]. Neurotoxicity can be presented with central or peripheral 
nervous system findings such as neurobehavioral symptoms, extrapyramidal 
signs, and peripheral neuropathy. Peripheral nerve fibers are affected distinctly 
by neurotoxicant injury. Mild or severe polyneuropathy involves the peripheral 
nerves, affecting the myelinated, thinly myelinated, and unmyelinated fibers. A 
wide variety of etiological factors can cause polyneuropathy. In addition to frequent 
causes such as diabetes mellitus, alcohol abuse, the peripheral nervous system is 
vulnerable to several rare conditions [2]. Toxic peripheral neuropathies are caused 
by various chemicals, a basic form of acquired polyneuropathy [3]. Neurotoxicity 
may develop when exposed to heavy metals, solvents chemotherapeutics, mono-
mers, gases and pesticides. The focus of this chapter includes signs, symptoms, 
pathophysiology, and treatment options of several neurotoxic agents that cause 
peripheral neuropathy.
2. Heavy metals
Heavy metals are naturally occurring elements with a high weight and a density 
at least five times greater than water [4]. In other words, any toxic metal can be 
defined as heavy metal, regardless of its atomic weight or density [5]. The industrial 
activities of the modern world have caused a massive rise in human exposure to 
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heavy metals, and heavy metals have harmful effects on human health [6]. Heavy 
metals’ contamination of water and air is an environmental threat, and hundreds of 
millions of people are being exposed worldwide. The concentration of heavy metals 
in water supplies, air, and food is evaluated in this respect [7, 8].
Heavy metals such as arsenic (As), lead (Pb), mercury (Hg), aluminum (Al), 
and cadmium (Cd) do not have any particular role in an organism and can be toxic 
even at low levels [9]. On the contrary, it has been reported that some of these heavy 
metals such as iron, magnesium, selenium, copper, zinc, cobalt, nickel, molybde-
num, chromium, and manganese are essential nutrients that have functional roles for 
various diverse biochemical and physiological functions in the body [10]. However, 
in over adequate amounts, they may cause toxicities. Acute and chronic toxic effects 
of heavy metals have an impact on different organs of the human body. In addition to 
the nervous system disorders, gastrointestinal and kidney dysfunction, skin lesions, 
vascular damage, immune system dysfunction, birth malformations, and cancer are 
examples of the complications of heavy metals toxic effects [8, 11, 12].
2.1 Lead
Lead is a toxic heavy metal in different sources such as contaminated drinking 
water, battery manufacture, cosmetics, leaded gasoline, lead-based paint, cans, 
glazed ceramics, traditional herbal medicine products, water pipes, jewelry, tobacco 
smoke, and electronic cigarettes, and toys. Lead exposure can be considered a public 
health concern, especially in early childhood, because children have increased 
hand-to-mouth activity, so they are more at risk [13, 14]. While the half-life of Pb 
in the bloodstream is about 35 days, it is stored in bones for approximately 30 years 
[15, 16]. Oxidative stress, alterations in membrane biophysics, dysregulation of cell 
signaling, and the impairment of neurotransmission are considered the complex 
underlying mechanisms of lead-induced neurotoxicity [17].
One of the most critical endpoints of Pb toxication is neurological effects. Pb 
toxication frequently causes neuropathy in adults, while encephalopathy is mainly 
seen in children. Exposure to high Pb levels causes encephalopathy with signs such 
as hyperirritability, cerebellar findings, seizures, unconsciousness, and coma. It is 
reported that exposure to low Pb levels has been associated with impaired cogni-
tive and intellectual function in children [18, 19]. In occupational exposure, it is 
reported that neurological signs and symptoms include weakness, forgetfulness, 
irritability, headache, impotence, decreased libido, vertiginous symptoms, and 
paresthesia in Pb exposure workers. Moreover, increased prevalence and severity 
of white matter lesions, changes in nerve conduction velocity, and alterations of 
somatosensory evoked potentials were documented [18, 19].
In lead toxicity, motor-predominant polyneuropathy, which causes the develop-
ment of wrist-drop, may present. Additionally, because of secondary to autonomic 
nerve involvement, constipation may accompany [20]. After forbidden the usage 
of leaded gasoline, changes in lead mining practices, and the abandonment of 
lead-based paint, human exposure to the primary sources of Pb decreased. So the 
incidence of overt lead toxicity induced polyneuropathy decreased [21].
2.2 Arcenic (As)
Arsenic is an environmental toxin, and this heavy metal is widely distributed to 
the earth. Hundreds of millions of people consume inorganic contaminated tube 
well water [22, 23]. Burning the charcoal and metal foundry activities are known to 
cause atmospheric deposition of As. Excessive pesticides and fertilizers and mining 
use cause soil contamination with As [24, 25]. While As often exists in the world 
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crust in the trivalent atomic state (inorganic) with other heavy metals such as Pd, 
iron, copper, it is generally oxidized to pentavalent form in the soil and water. It is 
reduced to in trivalent atomic state in low oxygen situations, such as deep seawater 
[26]. Inorganic As is more potent and has been implicated in neurotoxic effects. The 
inorganic form should be distinguished from the non-neurotoxic organic As found 
in some fish and shellfish [21].
It is reported that traditional folk medicines can be the other sources of As [27, 28]. 
Some herbal medicines commercially available have been reported to contain heavy 
metals such as lead, mercury, and arsenic. Using these products may cause heavy 
metal toxicity and secondary peripheral neuropathy [26]. As causes various adverse 
effects on human health such as carcinogenic and non-carcinogenic [26].
The exact metabolic pathways of As are yet to be proved. However, oxidative 
methylation and glutathione conjugation are the primary pathways suggested [29]. 
The primary mechanism in As-induced neurological pathologies has been suggested 
oxidative stress with Vitro and in vivo studies [9]. While exposure to high levels of 
As induces primarily central nervous system findings, exposure to low levels causes 
primarily peripheral nervous system findings [18].
Single high dose exposure to As may lead to severe gastrointestinal and systemic 
symptoms such as nausea, diarrhea, vomiting, pain, dehydration, and weakness. 
It is usually the result of suicide- homicide or accidental poisoning. If the patient 
survives acute poisoning with As, neurological symptoms such as light-headedness, 
weakness, delirium, encephalopathy, and peripheral neuropathy develop [30].
Chronic neurological symptoms of As exposure are delirium, encephalopathy, 
and also peripheral neuropathy. In neuropsychological tests, while psychomotor 
speed and attentive processes were mildly impaired, verbal learning and memory 
were severely impaired [31, 32]. It is known that peripheral neuropathy may last 
for several years or even life-long, but on the other hand, in severe cases, diffuse 
sensorimotor polyradiculoneuropathy may be seen, similar to the Guillan–Barré 
syndrome. At the same time, chronic As exposure can cause painless sensory-
predominant peripheral neuropathy [32].
The diagnosis of arsenic toxicity can be made by demonstrating high urinary 
and increased arsenic levels in the nails and hairs. Serum arsenic level estimation 
is not recommended because of the rapid clearance of arsenic. There is no gold 
standard specific treatment for chronic arsenic toxicity. For acute arsenic toxicity 
treatment, chelating agents such as BAL, D-penicillamine, and meso-2,3-dimercap-
tosuccinic acid are mainly used [33].
2.3 Mercury (Hg)
Mercury is heavy metal in the air, water, and soil in three chemical forms;  
metallic/elemental, inorganic, and organic Hg (methyl mercury and ethyl mercury). 
The elemental Hg is liquid at room temperature and can evaporate quickly. The 
vapor form of Hg is more dangerous and can is readily absorbed from the lungs 
(80%) and distributed throughout the body [8]. A wide variety of fields in that Hg 
have been used, such as gold mining, fluorescent light bulbs production, ingre-
dients of antiaging creams, fungicides to protect plants against infections, and 
protection in multidose vials of vaccines [34, 35].
In the middle of the 1950s, around 200.000 people have affected by the  
consumption of organic Hg-contaminated fish in Minamata Bay, Japan. Because 
of chronic Hg toxicity, neurological signs and symptoms occurred, such as ataxia, 
weakness, numbness, disturbance in speech, chewing, and swallowing. Infants 
born with severe developmental disabilities from the poisoned pregnant women 
were reported. After that, the illness was called Minamata disease [36].
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It is reported that organic mercury influences the dorsal root and trigeminal 
ganglia and causes paresthesia, usually just before causing widespread CNS 
dysfunction [20]. In nerve conduction studies, motor abnormalities were much 
more frequently reported than sensory abnormalities. Most frequently, findings 
were prolonged latencies and reduced amplitudes in both motor and sensory 
nerves. Nevertheless, interestingly, those abnormalities were shown more often in 
upper extremities, not lower extremities, a finding that differs from expectations 
[37]. Electromyography (EMG) was less frequently performed in the studies but 
reported results were always abnormal. The most frequently reported EMG find-
ings (fibrillations, positive waves) were suggestive of active denervation and also 
reinnervation (prolonged motor unit potential duration, polyphasic motor unit 
potential durations) [38]. Electromyography (EMG) was less frequently performed 
in the studies but reported results were always abnormal. The most frequently 
reported EMG findings (fibrillations, positive waves) were suggestive of active 
denervation and also reinnervation (prolonged motor unit potential duration, 
polyphasic motor unit potential durations) [20].
2.4 Cadmium (Cd)
Cadmium is a highly toxic heavy metal. According to Agency for Toxic Substance 
and Disease Registry, Cd is the 7th most toxic heavy metal. The biological half-life 
of Cd is about 20–30 years in humans [39]. Cd exists naturally in unrefined rocks. 
Several sources of human exposure to Cd include mining works, contaminated 
groundwater use, commercial products (batteries, color pigments, several alloys, 
and Polyvinyl chloride, phosphate fertilizer) [40].
Exposure to Cd can be occurred by inhalation and also ingestion. It can accumu-
late into the lungs, olfactory bulb, and kidney [40]. Suggested mechanisms of Cd 
neurotoxicity include increased lipid peroxidation associated with oxidative stress 
and causing injury to the microvasculature of the brain. Experimental studies show 
that rats exposed to Cd, accumulation in choroid plexus, and Cadmium-related 
lipid peroxidation were demonstrated in brain areas such as the cerebellum and 
cerebral cortex [41, 42]. Cd neurotoxicity might be caused by defective neurogen-
esis, lead notably reduced neuronal differentiation and axonogenesis, leading to 
neuronal cell death [43].
Exposure to Cd causes very different neurological signs and symptoms of both 
the peripheral and central nervous systems. These are mental retardation, learn-
ing disabilities, behavioral pathologies [44]. Moreover, there is growing evidence 
about Cd-dependent neurotoxicity being one of the possible etiological factors of 
neurodegenerative diseases such as Alzheimer’s, Parkinson’s diseases, and sporadic 
amyotrophic lateral sclerosis [45, 46]. However, Little is known about the influence 
of cadmium on the peripheral nervous system. Experimental studies have shown 
that Cd can be a potent neurotoxicant for the peripheral nervous system. Viaene 
et al. investigated the influence of Cd on polyneuropathy in 13 retired, long-term 
Cd-exposed workers. They performed the neurological clinical examination, nerve 
conduction studies, and needle EMG were performed in the study. 54% of the 
retired Cd workers were diagnosed with polyneuropathy. The authors concluded 
that increased Cd body burden promotes PNP development at older age [47].
There is no consensus in the literature regarding the treatment of Cd toxicity. 
While clinical treatment protocols exist for the use of Ethylene Diamine Tetra 
Acetic Acid (EDTA), 2,3-Dimercapto-1-propane sulfonic acid (DMPS), and meso-
2, 3-dimercaptosuccinic acid (DMSA), there are limited human studies. EDTA 
is the agent most widely accepted for clinical use. It should be noted that these 
chelation treatments applied during acute poisoning may aggravate damage to the 
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renal tubules. EDTA, which has a long history of safe use, is approved by the FDA to 
chelation heavy metals. It should not be given faster than one gram per hour nor in 
dosage greater than three grams per session. Cd is also significantly present in sweat 
during sauna, which appears to be a moderately successful modality for reducing 
the body burden of Cd without risk of tubular damage [48–50].
2.5 Tallium (T.I.)
Thallium is one of the heavy metals found in the earth’s crust. Tl is colorless, 
odorless, and tasteless, and it has been used as a pesticide and rodenticide. Although 
the use of T.I. in this field has been abandoned in most western countries, there 
are still countries where it continues to be used. Thallium has been used in a wide 
variety of industries fields such as electronics, lamps, jewelry, pigmentation [51].
Thallium can contaminate by skin contact, inhalation of contaminated air, or 
food consumption from contaminated soil or water. Suggested mechanisms of T.I. 
neurotoxicity include lipid peroxidation and lysosomal enzyme beta-galactosidase 
in brain regions [52].
Toxication of T.I. causes neurological and non-neurological disorders. Anorexia, 
vomiting, gastrointestinal bleeding, abdominal pain, alopecia, cardiac arrhythmias 
are the best-known disorders. In a dose-dependent manner, neuropsychiatric signs 
have been reported as following; coma, delirium, seizure, hallucination, fatigue, 
emotional changes, ataxia, and loss of sensation, cranial neuropathy, and polyneu-
ropathy [51, 53, 54]. Thallium-related polyneuropathy can become evident within 
1–2 days. It is reported that a painful sensory-motor polyneuropathy mimicking 
Guillain-Barre’s syndrome occurs. In delayed admission, patients are more prone to 
severe polyneuropathy and other neurological disorders [51, 55].
Treatment for thallium intoxication consists of termination from exposure,  
supportive care, and enhanced elimination. Prussian blue is approved as an oral agent 
to prevent absorption of thallium. It is reported that hemodialysis combined with the 
usage of Prussian blue helps treat patients even delayed admission [51, 55, 56].
3. Solvents
Solvents used in industry as degreasing agents, adjuvants, thinners, and  
cleaners are widespread. N-Hexane, carbon disulfide, ethylene oxide are widely 
used solvents [57]. Adhesives containing n-hexane are also widely used in the 
manufacture of leather goods [58]. Repeated occupational exposure of solvents can 
be both inhalation and skin contact. While the hexane concentration limit of organ 
damage through prolonged or repeated exposure is suggested as 5%, the organic 
solvents used in the adhesives may contain a higher percentage of n-hexane [59]. 
The toxic effects of organic solvents can be considered a public health problem 
even though regulations have been made that reduce usage limits [60]. The organic 
solvent syndrome is the mildest form of chronic exposure. Irritability, fatigue, and 
reversible difficulty to concentrate are the related symptoms [61]. The neurotoxicity 
of solvents may occur in both the peripheral nervous system and central nervous 
system [62].
3.1 N-hexane
The molecular mechanisms of peripheral neuropathy induced by hexane 
exposure have been investigated in several studies. ɣ-diketone 2,5-hexanedione, 
which is a neurotoxin, is the metabolite of n-hexane. ɣ-diketone 2,5-hexanedione is 
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the cause of sensory or sensory-motor peripheral neuropathy [63–66]. According 
to the suggested mechanism, the accused metabolite reacts with amino groups of 
proteins, including neuroproteins. Lysine-rich neuroproteins are especially vulner-
able, including microtubule-associated proteins required for axonal transport. 
Disruption of axonal transport causes consecutive degenerative changes resulting in 
localized demyelination and remyelination, with initial changes in the most exten-
sive and most prolonged axons in peripheral nerves and the spinal cord, with simi-
lar changes in shorter nerve fibers at a later stage. It results in distal symmetrical 
sensorimotor neuropathy supported by central-peripheral distal axonopathy [63].
Detailed neurological and neuropsychological examinations are recommended 
to confirming the clinical findings of central and peripheral nervous system 
dysfunctions in case of suspicion of toxication. Sensory abnormalities such as 
insensitivity to pinprick and touch, impaired two-point discrimination, changes 
in sensation to position, vibration, or temperature, diminished deep tendon 
reflexes are common neurological findings. Peripheral neuropathy is characterized 
by symmetrical progressive distal sensory and motor impairment [61, 62, 64]. 
Nerve conduction studies and electromyography should be performed to confirm 
peripheral neuropathy. It is reported that severe exposure and affected patients 
may develop muscle atrophy and foot drop [62]. Typical electrophysiological 
findings increase in distal latencies, slowing of nerve conduction velocities, 
conduction block with temporal dispersion, and the slowing down of transmission 
in electromyography in subjects with severe neuropathy [58, 62]. Neuroimaging 
Cranial magnetic resonance imaging (MRI) should be performed to detect the 
atrophic changes in the frontal lobes and cerebellum and white-matter lesions 
described after exposure to certain solvents [67, 68]. It is reported that acute, low-
dose exposures might be related to specific changes in test performance, which 
improve after withdrawal from exposure. However, chronic exposure can also be 
associated with permanent cognitive changes [67].
3.2 Carbon disulfide
Carbon disulfide (CS2) is an organic solvent used for various industrial purposes, 
such as an insecticide, fresh fruit conservation, disinfectant against insects [69]. CS2 
is a significant metabolite of the drug disulfiram used as a dissuasive for alcohol abuse. 
The occupational CS2 exposure can be by inhalation and skin contact. It is known 
that the highest degree of exposure is in the viscose rayon industry [70]. Exposure to 
carbon disulfide is likely to occur for the general population by inhaling contaminated 
ambient air, eating vegetables and fruits, or other food products containing carbon 
disulfide [69]. Since carbon disulfide has lipophilic nature, the distribution of C.S. 2 
is easily in organs such as the brain and liver. C.S. 2 is metabolized to thiocarbamates 
in these organs, and it is considered that dithiocarbamates can take part in neurotoxic 
effects [71].
According to acute or sub-acute high-level exposures of CS2 can lead to uncon-
sciousness, hallucinations, emotional lability, extrapyramidal signs, and polyneu-
ropathy [69, 70]. It is reported that exposure of 200 to 500 ppm may cause death 
[69]. Peripheral neuropathy and extrapyramidal signs have been reported following 
chronic occupational low-level exposures. In low level (10 to 40 ppm) exposure, 
peripheral neuropathy may be asymptomatic and detected only electrophysiologi-
cally. As the concentration of CS 2 increases (20 to 60 ppm), a progressive senso-
rimotor distal asymmetrical polyneuropathy appears [72].
In neurological examination, findings include; paresthesia and dysesthesia tend 
to occur in a ‘stocking and glove’ distribution, loss of ankle and patellar reflexes, 
and diminished pain, touch, and vibration sensation in the distal lower limbs. In 
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some cases, recovery may be slow and incomplete, possibly because of residual 
axonal damage [73].
There is no typical clinical profile and routine laboratory tests, including 
cerebrospinal fluid (CSF) examination. Nevertheless, CSF should be performed for 
differential diagnosis. Nerve conduction studies and electromyography should be 
performed to confirm peripheral neuropathy. It is reported that long-term exposure 
and a cumulative dose of CS2 exposure are related to electrophysiological findings 
[74]. In the electrophysiological examination, reduced motor and sensory ampli-
tudes, slightly slowed motor conduction velocities prolonged distal latencies are 
reported in exposed patients with neuropathy symptoms. In the same patient group, 
needle EMG revealed chronic, length-dependent denervation with decreased 
recruitment, large motor units, and fibrillation potentials [75].
3.3 Ethylene oxide (EO)
Ethylene oxide is a powerful sterilizer for medical materials and antiseptic for 
furs and some foods. It is a gas at room temperature. The occupational EO exposure 
can be by inhalation. Since EO is a water-soluble substance, it can quickly spread to 
all organs shortly after inhalation exposure [72]. EO is a potent alkylating agent and 
can interact with all cellular components, including DNA [76].
The principal neurotoxicant effect of EO is polyneuropathy. EO-related distal 
symmetrical axonal polyneuropathy has been reported in several cases reports in 
the 1980s, and Ohnishi et al. established an experimental model of EO neuropathy 
[77–80]. Kuzuhara et al. showed axonal degeneration with mild changes of the 
myelin sheath in sural nerve biopsies [79]. Neurotoxic effects may develop in both 
intermittent high doses and chronic prolonged low-dose exposure [72]. Gross et 
al. reported four cases who had occupational EO exposure. One of the cases had 
encephalopathy syndrome, and three of them had polyneuropathy [80]. In clini-
cally symptomatic cases, distal extremity numbness and weakness, diminished 
sensation in the feet and hands can be initial symptoms. However, some of the 
cases can be asymptomatic. The electrophysiological examination reported reduced 
motor and sensory amplitudes and mildly slowed motor and sensory nerve conduc-
tion velocities [80, 81]. Gradual improvement of neurotoxicant effects was found 
associated with withdrawal from exposure [81].
4. Medications and peripheral nervous system toxicity
Antineoplastic drugs’ most frequent and sometimes serious complication is 
chemotherapy-induced peripheral neuropathy (CIPN). The estimated prevalence of 
CIPN is 19–85% [82]. Compared to other peripheral neuropathies, such as painful 
diabetic polyneuropathy, patients with CIPN are likely to develop more severe symp-
toms, suffering from pain affecting both feet and hands, with faster progression. 
The high prevalence of CIPN among patients with cancer poses a serious problem for 
both patients and doctors administering the treatment. Due to the CIPN and related 
symptoms, sometimes it may be necessary to interrupt, stop, or reduce the dose of 
drugs, limiting the treatment’s efficacy [83].
Platinum analogs (Cisplatin, oxaliplatin), taxanes (Paclitaxel), vinca alka-
loids, and proteasome inhibitors (bortezomib) are the most commonly preferred 
antineoplastic medications. These are successfully used as first-line treatment for 
several solid and blood cancers, such as breast, lung, colorectal, gastric cancers, 
and multiple myeloma [84]. Although these antineoplastic medications have 
different chemical structures and mechanisms, chemotherapy-induced peripheral 
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neurotoxicity (CIPN) is one of their common side effects. The occurrence of CIPN 
varies according to the chemotherapeutic drugs, dose, duration of exposure, and 
method of assessment [85]. The highest rate of CIPN is reported in platinum 
analogs (70–100%), taxanes (11–87%), thalidomide, and its analogs (20–60%), and 
ixabepilone (60–65%) [86].
4.1 Platinum analogs; cisplatin, carboplatin, oxaliplatin
Platinum analogs interact with DNA, forming platinum-DNA compounds and 
cause apoptotic cell death. Most platinum analogs cause some degree of neurotoxic-
ity. Dorsal root ganglion (Drg) is considered to be the primary target of neurotoxic-
ity. It has been shown that platinum analogs cause apoptosis in dorsal root ganglia 
and morphological changes in the nucleus in-vitro [84]. Because of the lack of 
blood–brain barrier protection and be vascularized by fenestrated capillaries, the 
nuclei of Drg neurons are vulnerable to chemically-induced damages [87]. Platinum 
analogs induced peripheral neuropathy is a sensory neuronopathy caused by direct 
damage to Drg neurons, leading to an anterograde axonal degeneration. According 
to sensory neuronopathy, altered touch sensation, paresthesia in the distal extremi-
ties, tingling, altered touch sensation, proprioceptive loss, areflexia, and sensory 
ataxia occur. Patients frequently experience painful sensations, including spontane-
ous burning, electric shock-like pain, along with mechanical or thermal allodynia 
or hyperalgesia. Neuropathic pain symptoms have been reported, often even after 
treatment discontinuation [88, 89].
Since the 1980s, Cisplatin has been used to treat testicular, ovarian, and small 
cell lung cancers. Cisplatin administration induced severe toxicity, especially to the 
kidneys and nervous system [90]. Cisplatin causes primarily sensory neuropathy, 
characterized by distal parenthesis, progressing to proprioceptive loss, areflexia, 
and sensory ataxia [88]. Symptoms arise after cumulative doses above 300 mg/
m2. Severe symptoms related to neuropathy have been reported to occur three to 
six months post-treatment cessation [91]. Electrophysiological studies have typi-
cally shown marked reduction in sensory action potential amplitudes with relative 
preservation of conduction velocity, indicative of axonal loss [84, 91]. Motor and 
autonomic symptoms and signs are infrequent but may occur in severe cases. 
Treatment with platinum analogs has been rarely associated with acute inflamma-
tory demyelinating polyradiculoneuritis in patients with solid tumors [92].
Carboplatin is known to be less toxic, with neuropathy observed in 13–42% of 
patients. At the same time, carboplatin may induce mild neurotoxicity in quarter 
patients, with moderate to severe neurotoxicity in 5% of patients [93]. Peripheric 
neurotoxic side effects are common with high doses (800–1600 mg/m2) [94]. 
Electrophysiological studies reveal a reduction in compound sensory and motor 
amplitudes. Experimental studies have reported that at very high doses (10–15 mg/kg), 
carboplatin induces neurotoxicity and associated platinum deposition in the dorsal 
root ganglion, similar to Cisplatin [84].
Oxaliplatin has been effectively used as a first-line therapy against colorectal 
cancer. Its neurotoxicity may develop both acute and chronic. Acute and rapidly 
reversible peripheral neuropathy occurs in approximately 65–98% of patients 
within hours of drug infusion at a dose ranging 85–130 mg/m2 and may last up 
to one week. In 12 cycles of chemotherapy received, symptoms may persist up 
to 21 days or longer. Myelotoxicity and enteric and peripheral neuropathy may 
be induced by chemotherapy with oxaliplatin [95]. Cold-induced neuropathic 
symptoms are the most important difference in the clinical presentation between 
oxaliplatin and cisplatin-induced neuropathy [96]. Chronic peripheral neuropathy 
occurs in approximately 50–70% of patients, described as a pure sensory, axonal 
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neuropathy [95]. Patients frequently experience distal paresthesia, sensory ataxia, 
jaw pain, leg cramps. Electrophysiological studies of oxaliplatin-induced peripheral 
neuropathy reduce the sensory action potentials with preserved motor amplitudes 
and conduction velocities. However, spontaneous activity can be obvious, suggest-
ing an immediate effect of the drug on the axonal excitability rather than structural 
damage [84, 97].
4.2 Taxanes; paclitaxel
Paclitaxel, docetaxel, cabazitaxel are the class of taxanes that act on microtu-
bules, interfering with the normal cycling of microtubule depolymerization and 
polymerization. The incidence of CIPN according to taxanes may be very high 
(11 to 87%), and the highest rates are reported for Paclitaxel [98]. Neuropathy 
caused by taxanes usually emerges as a dominant sensory neuropathy with the 
stocking-and-glove distribution. The manifestations are paresthesias, dysesthesias, 
numbness, altered proprioception, and loss of dexterity predominantly in the toes 
and fingers. Motor and autonomic involvement are infrequent [99]. Neurological 
symptoms and findings are dose-dependent and tend to improve after stopping 
the treatment. However, some patients experience symptoms up to 1–3 years and 
sometimes lifelong after the therapy [100]. Microtubule disruption, mitochondrial 
dysfunction, axonal degeneration, altered calcium homeostasis, altered expression 
and function of ion channels, production of pro-inflammatory cytokines are the 
suggested underlying mechanisms of CIPN [101, 102].
Paclitaxel is a microtubule-binding antineoplastic drug commonly used to treat 
various solid tumors like lung, breast, and ovarian cancer. Paclitaxel is highly potent 
against proliferating neoplastic cells, but neurons not dividing cells are vulnerable to 
Paclitaxel. The treatment with paclitaxel affects the peripheral nervous system and 
primarily causes sensory axonal polyneuropathy [103]. Peripheral nerves biopsies 
have revealed a pathology of axonal degeneration, secondary demyelination, and, in 
cases of severe neuropathy, nerve fiber loss has also been observed [104].
4.3 Vinca alkaloids; vincristine
Vinca Alkaloids are developed from the Madagascar periwinkle plant, including 
vincristine, vinblastine, vinorelbine, and vindesine. These drugs are commonly 
prescribed to treat various tumors, such as Hodgkin and non–Hodgkin lymphoma, 
testicular cancer, and non–small cell lung cancer [102]. Vinca alkaloids have well-
documented effects on microtubules – including binding to tubulin and inhibiting 
microtubule Dynamics [105].
Vincristine was approved in July 1963 by the United States Food and Drug 
Administration (FDA). It is one of the most common anticancer drugs used in 
pediatrics oncology. However, its clinical use is accompanied by severe side effects, 
such as peripheral neuropathy and neuropathic pain leading to treatment discon-
tinuation. Both sensory and motor dysfunctions characterize peripheral neuropathy 
related to vincristine [106]. The duration and therapeutic doses received by patients 
directly affect the severity of symptoms. Besides sensory symptoms, patients also 
experienced muscle weakness and cramping. Changes in axonal transport and 
dorsal root ganglia resulting in Wallerian degeneration, altered ion channels activity 
and hyperexcitability of peripheral neurons, production of pro-inflammatory cyto-
kines are the suggested underlying mechanisms of vincristine-induced peripheral 
neuropathy [101].
Vincristine use in Charcot–Marie–Tooth disease (CMT) patients has a black box 
warning added by the FDA. The CMT patients with the ERG2 gene mutation and 
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polymorphism in the CEP72 gene are associated with increased risk and severity of 
drug-induced neuropathy [107, 108].
There is no specific treatment for vinca alkaloid-induced peripheral neuropathy. 
Pyridoxine or pyridostigmine can be having a certain efficacy in vincristine-
induced neuropathy. A topical capsaicin cream was demonstrated to give benefit 
in peripheral neuropathy. In neuropathic pain, carbamazepine, imipramine, or 
lignocaine can be used [101].
4.4 Proteasome inhibitors; bortezomib
Bortezomib is a reversible proteasome inhibitor antineoplastic drug that is 
successfully used against multiple myeloma and some types of solid tumors. It was 
first described as an inflammation inhibitor, but with its cytotoxic effects, it began 
to be used in cancer therapy. Bortezomib was approved in 2003 by FDA as a single 
agent against advanced myeloma but is now mostly used in combination therapies 
[109]. Although bortezomib is generally well tolerated, the most frequent limiting 
factor for its clinical use is a painful peripheral neuropathy side effect. Bortezomib-
induced peripheral neuropathy is attributed to paresthesias, dysaesthesias, burning 
sensations, numbness, sensory loss, reduced proprioception, and vibratory sensa-
tion. Besides these symptoms and signs, demyelinating neuropathy may also be 
present. Deep tendon reflexes and autonomic innervation of the skin are reduced in 
patients treated with bortezomib [110]. Chronic, distal, and symmetrical sensory 
peripheral neuropathy is typical neuropathy induced by bortezomib.
Neuropathic pain symptoms have been reported to continue for weeks, months, 
or even years after treatment discontinuation.
Bortezomib-induced peripheral neuropathy is reported in approximately 
one-third of the patients [111]. Suggested mechanisms of bortezomib-induced 
peripheral neuropathy are increased sphingolipid metabolism in astrocytes, inflam-
mation related to TNFa and IL-1, mitochondrial damage, reactive oxygen radical 
production, and alteration in Ca++ signaling [101].
5. Others
5.1 Acrylamide
Monomeric acrylamide is a potent neurotoxin used in different industrial and 
laboratory processes. Acrylamide is readily absorbed by inhalation, ingestion, 
or dermal contact. The acrylamide exposure affects the central nervous system 
(CNS) and peripheral nervous system (PNS). Chronic and high-level exposure to 
this water-soluble chemical mostly causes peripheral neuropathy. The peripheral 
neuropathy causes impairment in the arms and legs of exposed workers. Several 
studies reported that short-term occupational exposure to acrylamide resulted in 
weakness of lower extremities, loss of deep tendon reflexes and sensations in distal 
limbs, and numbness preceded by skin peeling from the hands [112–114]. Moreover, 
it has been shown that longer exposure involved more severe symptoms, including 
cerebellar dysfunction followed by peripheral neuropathy. Based on numerous 
investigations and risk assessments, acrylamide is generated in food preparation 
processes involving high temperatures [115, 116]. Different pathogenetic mecha-
nisms were hypothesized; however, the exact mechanism of action is not completely 
elucidated. Like other toxic neuropathies, the prognosis of neuropathy is associ-
ated with the degree of central axonal degeneration. Three important hypotheses 
currently considering acrylamide neurotoxicity include inhibition of kinesin-based 
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fast axonal transport, alteration of neurotransmitter levels, and direct inhibition of 
neurotransmission [117].
5.2 Styrene
Styrene is a colorless solvent found in paints, plastics, and resins. It is one of the 
essential monomers usually used in plastic production. This compound can cause 
intoxication when inhaled in high concentrations for longer periods. There are 
few case reports regarding styrene-induced peripheral neuropathies. Early studies 
demonstrated abnormal neurological findings in humans exposed to styrene in low 
doses [118]. Styrene-induced peripheral neuropathy is characterized by neuropathic 
symptoms that start within a few days after significant exposure to styrene. Goba 
et al. reported that two workers presented with styrene-induced neuropathy. The 
workers had sensory-motor peripheral neuropathy of a demyelinating type [119].
5.3 Organophosphates
Organophosphates (OP) are chemical substances involved in the main  
components of herbicides, pesticides, and insecticides. Acute or chronic exposure 
to organophosphates causes several toxic effects in humans and animals. The expo-
sure to organophosphates might be accidental or intentional. The organophosphate 
intoxication may occur after exposure to pesticides, either through occupational 
contact or suicide attempts. Acute toxic effects and delayed toxic neuropathy are 
related to central and peripheral nervous system involvement. The main effect 
of OP exposure is poisoning; however, peripheral neuropathy has been linked to 
chronic exposure. Several recent cases were reported associated with organophos-
phate-induced delayed neuropathy (OPIDN) after ingestion of organophosphate 
insecticides. The peripheral neuropathy associated with organophosphate intoxica-
tion may be seen with mild exposure. The mechanism of OPIDN is explained by 
loss of function of both motor and sensory axons located distally and ascending 
and descending tracts of the spinal cord [120, 121]. Organophosphate-induced 
delayed neuropathy is an uncommon clinical condition characterized by a distal 
paresis in the lower limbs and sensory symptoms. Electrophysiological findings 
show motor axonal neuropathy. The delayed onset of peripheral neuropathy and 
axonal motor involvement without a progressive course is needed for the diagnosis. 
Organophosphates can irreversibly bind to acetylcholine esterase (AChE) and 
prevent the breakdown of acetylcholine (ACh). The liberation of ACh overstimu-
lates the muscarinic and nicotinic receptors. The main mechanism of OPIDN 
development is related to the inhibition of neuropathy target esterase (NTE) via 
phosphorylation. Neuropathy target esterase is an essential integrated membrane 
protein in neurons that takes part in axonal maintenance [122]. Its activity plays a 
crucial role in axonal maintenance since it facilitates the transport of macromol-
ecules to the end of axons [120].
The symptoms are attributed to the effects on sensory and motor nerves with 
a typical axonal length-associated pattern. Lower extremities are predominantly 
affected. However, upper extremities are affected at higher OP exposure. The 
prognosis of peripheral neuropathy varies due to clinical involvement. It is primar-
ily associated with the age of the individual (a younger age is associated with mild 
neuropathy), type of organophosphate, the persistence of myelopathic features, 
pyramidal involvement, degree of CNS involvement to peripheral nerve dysfunc-
tion [120, 123, 124]. There is no treatment approved for OPIDN, and the recovery 
is slow and partial. Thivakaran et al. reported a 15-year-old female who developed 
OPIDN with a smaller dose of chlorpyrifos [124]. Akçay et al. reported a similar 
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case diagnosed with organophosphate-induced delayed neuropathy (OPIDN) 
complicated with central nervous system findings. They observed partial improve-
ment in muscle strength despite motor axonal polyneuropathy [125]. In addition, 
Moretto et al. reported electrophysiological findings in 11 patients with acute OP 
poisoning [126]. Three of these patients developed OPIDN, mainly sensory-motor 
polyneuropathy. The diagnostic approach should be made carefully in peripheral 
neuropathy patients, excluding other possible causes, especially those who did not 
display cholinergic toxicity before the onset of neuropathy. Early recognition of OP 
poisoning and a professional approach to intoxication can be life-saving.
6. Conclusion
Chemicals have toxic effects on the human body. Neurotoxicity demonstrates 
acute and chronic manifestations. A toxic chemical can produce an acute toxic 
response, besides prolonged exposure of a toxin may result in slowly developing 
chronic disease. In many cases, the putative neurotoxic damage present many years 
after initial exposure to the toxin. Therefore, the clinical signs elicited and symp-
toms expressed should be interpreted carefully. The neurotoxicity level and the 
circumstances of the exposure determine clinical presentation. The clinical signs 
and symptoms due to neurotoxicity may be expressed in central and peripheral 
nervous systems. Moreover, toxic agents disrupt cellular processes and result in 
epigenetic changes. While several heavy metals cause DNA damage which leads to 
carcinogenesis, the peripheral nervous system is also vulnerable to toxin-induced 
damage. A peripheral neuropathy may have its origin in the neurone, axon, myelin 
sheath or either Schwann cells. Patients may present with length-dependent senso-
rimotor peripheral neuropathy as well as mononeuropathy or radicular pathology. 
Organophosphates and acrylamide have been associated with severe damage to 
the motor nerve terminal. Many chemicals have the ability to cause axon damage 
including acrylamide, arsenic, carbon disulfide, n-hexane, lead, organic mercury, 
perhexilene, and thallium. Hexachlorophene and perhexilene have been involved in 
myelin disruption. Also, methyl mercury is well-known neurotoxin cause neu-
ronopathy. Here, we discuss the peripheral nervous system manifestations of heavy 
metals, solvents, chemotherapeutics, monomers, gases and pesticides in detail.
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